Image credit: Canva
Blood cancers such as leukemias or lymphomas often do not respond to standard treatments. A transplant of blood stem cells from a healthy donor, combined with certain drug therapies, can sometimes help people with these cancers. A clinical trial led by Christopher Kanakry, M.D., Lasker Clinical Research Scholar in the Center for Immuno-Oncology, is researching a drug therapy to reduce the potential side effects of blood stem cell transplants for blood cancers such as leukemias or lymphomas. The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact Jessica Bernhardt at (240) 552-2858 or jessica.bernhardt@nih.gov
Clinicaltrials.gov identifier: NCT05436418
NCI Protocol ID: NCI000613
Official Title: Phase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
